Keyphrases
Adjusted Odds Ratio
9%
Advanced Hepatocellular Carcinoma
17%
Bevacizumab
8%
Cancer Cases
12%
Cancer Patients
6%
Cigarette Smoking
5%
Clinical Significance
7%
Confidence Interval
38%
Diabetes
10%
Excessive Drinking
5%
Gene Polymorphism
5%
Genome-wide Association Study
8%
Genotype
10%
Growth Factors
7%
Hepatocellular Carcinoma
75%
Hepatocellular Carcinoma Patients
11%
Hepatocellular Carcinoma Risk
12%
Insulin-like
8%
Liver Transplantation
6%
Log-rank Test
6%
MD Anderson Cancer Center
5%
Median Overall Survival
5%
Metformin
5%
Odds Ratio
20%
Overall Survival
20%
Pancreatic Cancer
55%
Pancreatic Cancer Risk
13%
Pancreatic Ductal Adenocarcinoma
8%
Phase II Trial
6%
Polymorphism
6%
Prognostic Biomarker
7%
Progression-free Survival
8%
Risk Factors
15%
Single nucleotide Polymorphism
5%
Sorafenib
5%
Tumor
6%
Type 1 Diabetes Mellitus (T1DM)
5%
United States
9%
Unresectable Hepatocellular Carcinoma
6%
Vascular Endothelial Growth Factor
5%
Medicine and Dentistry
Alcohol Consumption
7%
Biological Marker
15%
Cancer
5%
Cancer Diagnosis
5%
Cancer Risk
7%
Case-Control Study
18%
Child-Pugh Score
6%
Cholangiocarcinoma
10%
Cohort Effect
5%
Diabetes
10%
Diabetes Mellitus
8%
Diseases
13%
Fluorouracil
6%
Genome Wide Association Study
9%
Glycon
5%
Hazard Ratio
6%
Hepatitis B Virus
6%
Hepatitis C Virus
9%
Hepatocellular Carcinoma
100%
Liver Cancer
6%
Liver Cirrhosis
11%
Liver Transplantation
10%
Logistic Regression Analysis
5%
Malignant Neoplasm
26%
Neoplasm
12%
Neuroendocrine Tumor
10%
Odds Ratio
22%
Overall Survival
23%
Pancreas Cancer
37%
Progression Free Survival
5%
Proportional Hazards Model
5%
Scoring System
7%
Smoking
5%
Somatomedin C
10%
Transcatheter Arterial Chemoembolization
5%
Vasculotropin
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acyltransferase
6%
Bevacizumab
8%
Biological Marker
12%
Case-Control Study
18%
Cytochrome
6%
Diabetes Mellitus
8%
Diseases
8%
Hepatitis B Virus
5%
Hepatitis C
5%
Hepatitis C Virus
8%
Liver Cancer
7%
Liver Cell Carcinoma
87%
Malignant Neoplasm
23%
Metformin
5%
Mutagenic Agent
6%
Neoplasm
13%
Overall Survival
21%
Pancreas Cancer
35%
Phase II Trials
10%
Progression Free Survival
8%
Recurrent Disease
5%
Sorafenib
8%
Vasculotropin
6%